H.C. Wainwright lowered the firm’s price target on FibroBiologics (FBLG) to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the company’s model to reflect an updated share count and tempered factor of patients receiving FibroBiologics’ novel diabetic foot ulcer treatment pending further clinical validation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG: